

# VA Committee

**Thursday, May 1 • 4:30 PM – 6:00 PM PT • Pacific HI**

## **Agenda**

### **A. Introductions and Opening Comments**

- *Stephen Bartlett, RPh, MSPH*

### **B. Studies for VA Consideration from SWOG**

1. **SN2426**, “A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma”

**Slated to activate May 15, 2025**

- Dr. Jimmy Ruiz, Wake Forest University HSC/ WG Hefner VA Medical Ctr  
VA Liaison on Early Therapeutics & Rare Cancers Committee

2. **S2409**, “PRISM: PReclision in SCLC via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)”

**Slated to activate August 4, 2025**

- Dr. Chao Hui Huang, VAMC Kansas City  
VA Liaison on Lung Cancer Committee

3. **S2414**, “A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)”

**Slated to activate in February 2025, officially activated on March 14, 2025**

- Dr. Chao Hui Huang, VAMC Kansas City  
VA Liaison on Lung Cancer Committee

### **C. VA Disease Committee Liaisons**

1. Updates, ongoing goals

- Dr. Jessica D. McDermott, Rocky Mountain Regional VA Medical Ctr

2. Open Committee Roles:

Cancer Care Delivery	Immunotherapeutics	Lung
Melanoma	Palliative Care	Prevention, Screening & Surveillance

How to Apply – [vamember@swog.org](mailto:vamember@swog.org)

## VA Committee

### **D. Current VA Stats**

*Accrual/sites – SWOG Report*

### **E. Other**

*1. VA and NIH - Future directions and considerations*

*2. AVAHO September 12-14, 2025*

*30th anniversary – Phoenix, AZ*

### **F. Future Meetings**

*3rd Qtr. Virtual VA Committee Meeting – July 8, 2025, 2:00-3:00 CT*

*SWOG Fall Group Meeting September 18-20, 2025 – Chicago, IL*